All 36 men (38 ROIs) enrolled to the study with PI-RADS 4/5 ROI and no clinically significant prostate cancer (csPA) on initial biopsy underwent repeat MRI, following which 14 ROIs were downgraded while 24 ROIs remained suspicious. Of the 20 ROIs that underwent repeat biopsy, 30% were benign, 30% were Gleason grade group (GGG) 1, and 40% were GGG ≥ 2.

Advancing Science

Repeat Biopsy Helps Catch Cancer in Patients with Suspicious Prostate Lesions

Study suggests patients with PI-RADS 4 or 5 ROI with an initial negative biopsy should be promptly re-evaluated.
Person Having Video Appointment with Doctor via Mobile Phone

Practice-Changing Medicine

Accelerating Telehealth Research for Cancer Care

Researchers at a first-of-its-kind center will study the impact of telehealth technology on cancer care in veterans.
A CT scan of the tracheal tumor.

Complex Case Spotlight

Resecting a Pediatric Tracheal Tumor with Robotic Surgery

With only 15 percent of the airway patent, treatment also required debulking via rigid bronchoscopy.
Light Micrograph of Section Through a Transitional Cell Carcinoma of the Bladder Wall

Advancing Science

Metabolic Enzymes Mark New Targets in Bladder Cancer

Key glycolytic enzymes acting as oncogenes may provide a novel path to overcoming cisplatin resistance.
Dr. Herbert Lepor and Dr. James S. Wysock Speaking Together in Hallway

Practice-Changing Medicine

Assessing Sexual Health After Partial Gland Cryoablation

Study offers a two-year view of erectile function following PGCA.
Dr. Benjamin G. Neel Sitting at Microscope in Lab

Expert Perspectives

Breakthrough Platform Unifies Targeted & Immune Therapies

Perlmutter Cancer Center director and co-creator of the HapImmune platform discusses the technology’s potential.
Load More